Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.
Draig Therapeutics has raised $65.0M in total funding. The most recent round was Series B. The last funding was announced in July 2026.
Draig Therapeutics's investors include British Business Bank, Janus Henderson Investors, SR One, SV Health Investors, Intermediate Capital Group.
Draig Therapeutics is headquartered in Cardiff, United Kingdom.
Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.
Draig Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Draig Therapeutics — Funding & Investors." VCBacked, July 14, 2026, https://www.vcbacked.co/company/draig-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Draig Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/draig-therapeutics
{{cite web |title=Draig Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/draig-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated